Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$23.68 USD

23.68
7,945,103

+0.14 (0.60%)

Updated Aug 8, 2025 03:54 PM ET

After-Market: $23.68 0.00 (0.00%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Smith & Nephew (SNN) has been gaining from several positive developments of late.

Zacks Equity Research

Why Is Baxter (BAX) Down 0.2% Since Last Earnings Report?

by Zacks Equity Research

Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

National Vision's Store Launches on Track Despite Cost Woes

by Zacks Equity Research

National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.

Zacks Equity Research

Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform

by Zacks Equity Research

Veeva's (VEEV) Vault platform sees a slew of developments in recent times.

Zacks Equity Research

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Zacks Equity Research

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

by Zacks Equity Research

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

Zacks Equity Research

Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis

by Zacks Equity Research

Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.

Zacks Equity Research

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

by Zacks Equity Research

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.

Zacks Equity Research

Genomic Health Test to Guide Chemo Per New Breast Cancer Rule

by Zacks Equity Research

This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.

Zacks Equity Research

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

by Zacks Equity Research

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Zacks Equity Research

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

by Zacks Equity Research

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

Zacks Equity Research

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio

by Zacks Equity Research

Stryker (SYK) gains from core segments in the second quarter of 2019.

Zacks Equity Research

Restoration Robotics (HAIR) Wins CE Mark for ARTAS iX System

by Zacks Equity Research

This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.

Zacks Equity Research

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

Zacks Equity Research

BAX vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAX vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) raises the revenue guidance for fiscal 2019.

Zacks Equity Research

Walgreens (WBA) Expands Partnership With Retail Giant Kroger

by Zacks Equity Research

The extended partnership deal with Kroger will help Walgreens (WBA) strengthen its market presence.

Zacks Equity Research

Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.

Zacks Equity Research

Here's Why You Should Invest in DaVita (DVA) Stock For Now

by Zacks Equity Research

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) in Your Portfolio

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.

Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

by Zacks Equity Research

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

Zacks Equity Research

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on Omnicell's (OMCL) prospects.